Savara Inc
SVRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001160308
No open-market purchases or sales by Savara Inc insiders were filed in the last 90 days; 180 institutions reported holding it in 13F filings for Q2 2026, worth $1.38B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −2 vs. previous quarter
- 180
- 13F valueReported value at the end of Q2 2026
- $1.38B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SVRA, Q2 2026
No superinvestor reported holding SVRA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Savara Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 (view filing) | Jun 22 | Same day | Lowrance David LChief Financial Officer | SSale | −394.5K | $5.68 | −$2.24M | −42.4%536.0K after | |
| Dec 19, 2025 (view filing) | Dec 19 | Same day | Ramsay David ADirector | SSale | −20.0K | $6.06 | −$121.2K | −0.8%2.53M after | |
| Jun 23, 2025 (view filing) | Jun 20 | 3 days | Hawkins Richard JDirector | PPurchase | +48.2K | $2.04 | +$98.4K | +71.7%115.5K after | |
| Jun 2, 2025 (view filing) | May 29 | 4 days | McCracken Joseph SDirector | PPurchase | +10.0K | $2.08 | +$20.8K | +4.0%260.8K after | |
| Apr 1, 2025 (view filing) | Mar 31 | 1 day | Ramsay David ADirector | PPurchase | +150.0K | $2.78 | +$417.0K | +6.3%2.51M after | |
| Dec 16, 2024 (view filing) | Dec 16 | Same day | Lowrance David LChief Financial Officer | SSale | −25.0K | $3.33 | −$83.3K | −6.2%381.0K after | |
| Dec 16, 2024 (view filing) | Dec 16 | Same day | Pauls MatthewCHIEF EXECUTIVE OFFICER | SSale | −54.7K | $3.31 | −$181.1K | −3.4%1.54M after | |
| Dec 16, 2024 (view filing) | Dec 16 | Same day | Hawkins Richard JDirector | SSale | −8.00K | $3.32 | −$26.6K | −10.6%67.2K after | |
| Nov 20, 2024 (view filing) | Nov 19 | 1 day | McCracken Joseph SDirector | PPurchase | +20.0K | $2.95 | +$59.0K | +10.5%210.8K after | |
| Nov 18, 2024 (view filing) | Nov 18 | Same day | Ramsay David ADirector | PPurchase | +100.0K | $2.88 | +$288.0K | +4.5%2.32M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Savara Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 24,471,264 | $150.7M | 9.49% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 17,600,621 | $108.4M | 6.45% | 00.0% | Unchanged |
| VR Adviser, LLC | 14,745,943 | $90.8M | 2.75% | +1,005,568+7.3% | Added |
| Nantahala Capital Management, LLC | 13,953,620 | $86.0M | 2.60% | +6,608,837+90.0% | Added |
| Deerfield Management Company, L.P. (Series C) | 13,569,000 | $83.6M | 0.87% | 00.0% | Unchanged |
| BlackRock, Inc. | 12,494,498 | $77.0M | 0.00% | +1,203,313+10.7% | Added |
| TCG Crossover Management, LLC | 12,362,205 | $76.2M | 1.83% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 9,720,852 | $59.9M | 1.30% | 00.0% | Unchanged |
| Polar Capital Holdings Plc | 9,541,786 | $58.8M | 0.17% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 7,932,545 | $48.9M | 0.00% | +148,632+1.9% | Added |